Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer

NCT04460430 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

12

Enrollment

OTHER

Sponsor class

Stopped premature termination due to lack of funding

Conditions

Breast Cancer

Interventions

DRUG: Neratinib + endocrine therapy

Sponsor

SOLTI Breast Cancer Research Group